Esperion Therapeutics entered a definitive agreement on March 3, 2026, to acquire Corstasis Therapeutics for $75 million upfront cash124.
The deal includes up to $180 million in regulatory and commercial milestone payments plus low double-digit royalties on Enbumyst sales and follow-on products12.
Enbumyst is an FDA-approved bumetanide nasal spray for treating edema in adults with congestive heart failure, liver, and kidney diseases14.
The acquisition is expected to close in Q2 2026, subject to customary conditions, with a termination date of May 1, 20261.
Esperion will finance the deal using existing credit facilities and royalty monetization with Athyrium Capital Management and HealthCare Royalty1.
Sources:
1. https://www.stocktitan.net/sec-filings/ESPR/8-k-esperion-therapeutics-inc-reports-material-event-2db49e18ac14.html
2. https://www.tradingview.com/news/tradingview:da69350a801f2:0-esperion-therapeutics-to-acquire-corstasis-for-75-million-upfront-plus-up-to-180-million-milestones/
4. https://www.fiercepharma.com/pharma/fishing-blockbusters-esperion-buys-out-corstasis-gaining-enbumyst